Our Diagnostic Platform
Detecting and managing cancer through multiplex proteomics and proprietary computational algorithms
Nonagen Bioscience® has developed a urine-based liquid biopsy platform that combines multiplex protein biomarker signatures, clinical data, and proprietary computational algorithms to generate actionable diagnostic and predictive insights.
Our Multianalyte Assays with Algorithmic Analyses (MAAAs) evaluate the expression patterns of multiple cancer-associated proteins and integrate these data with relevant clinical variables to generate indication-specific risk scores. This platform forms the foundation of the Oncuria® suite of tests for cancer detection, recurrence monitoring, and prediction of treatment response.
Commercial Products and Development Pipeline
Nonagen Bioscience® is translating its clinically validated biomarker and computational platform into diagnostic solutions designed to address important unmet needs across the cancer care continuum—from early detection and diagnosis to disease monitoring and treatment selection.
Oncuria® is Nonagen's lead commercial platform and is currently available as a suite of laboratory-developed tests (LDTs). Using a single multiplex, protein-based urine assay with indication-specific proprietary algorithms, Oncuria provides three distinct clinical applications:
Oncuria® Detect — Aids in the detection of urothelial cancer
Oncuria® Monitor — Monitors patients for bladder cancer recurrence
Oncuria® Predict — Predicts the likelihood of rapid failure following BCG therapy
Built on extensive clinical validation, the Oncuria platform is being advanced toward FDA-regulated in vitro diagnostic (IVD) applications, creating the potential for broader adoption and decentralized testing.
Pipeline snapshot
Oncuria® Clinical Evidence
Oncuria® has been evaluated across an extensive clinical development program designed to assess its performance and clinical utility throughout the bladder cancer care continuum. Studies have evaluated Oncuria for cancer detection, recurrence monitoring, and prediction of treatment response, including large prospective and multicenter clinical studies.
Together, these studies provide a growing body of clinical evidence supporting the use of Oncuria® as a noninvasive, urine-based diagnostic platform for the detection and management of bladder cancer.
A game-changing test for bladder cancer
Discover why Oncuria® has earned Breakthrough Device Designation status from the US Food and Drug Administration (FDA).